These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 26688732)

  • 1. Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.
    Dorkin HL; Staab D; Operschall E; Alder J; Criollo M
    BMJ Open Respir Res; 2015; 2(1):e000100. PubMed ID: 26688732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
    De Soyza A; Aksamit T; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
    Wilson R; Welte T; Polverino E; De Soyza A; Greville H; O'Donnell A; Alder J; Reimnitz P; Hampel B
    Eur Respir J; 2013 May; 41(5):1107-15. PubMed ID: 23018904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
    Aksamit T; De Soyza A; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
    Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma.
    Berger WE; Milgrom H; Chervinsky P; Noonan M; Weinstein SF; Lutsky BN; Staudinger H
    Ann Allergy Asthma Immunol; 2006 Nov; 97(5):672-80. PubMed ID: 17165278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids.
    D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H
    Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
    Murphy K; Noonan M; Silkoff PE; Uryniak T
    Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
    Saiman L; Marshall BC; Mayer-Hamblett N; Burns JL; Quittner AL; Cibene DA; Coquillette S; Fieberg AY; Accurso FJ; Campbell PW;
    JAMA; 2003 Oct; 290(13):1749-56. PubMed ID: 14519709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate.
    Nathan RA; Nayak AS; Graft DF; Lawrence M; Picone FJ; Ahmed T; Wolfe J; Vanderwalker ML; Nolop KB; Harrison JE
    Ann Allergy Asthma Immunol; 2001 Feb; 86(2):203-10. PubMed ID: 11258691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma.
    Corren J; Berkowitz R; Murray JJ; Prenner B
    Int J Clin Pract; 2003 Sep; 57(7):567-72. PubMed ID: 14529054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
    Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
    Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma.
    Holgate ST; Arshad H; Stryszak P; Harrison JE
    J Allergy Clin Immunol; 2000 May; 105(5):906-11. PubMed ID: 10808170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patients.
    Singh D; Magnussen H; Kirsten A; Mindt S; Caracta C; Seoane B; Jarreta D; Garcia Gil E
    Pulm Pharmacol Ther; 2012 Jun; 25(3):248-53. PubMed ID: 22497752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma.
    Karpel JP; Busse WW; Noonan MJ; Monahan ME; Lutsky B; Staudinger H
    Ann Pharmacother; 2005 Dec; 39(12):1977-83. PubMed ID: 16264062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.